

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 6, 2023**

**DELCATH SYSTEMS, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-16133**  
(Commission  
File Number)

**06-1245881**  
(IRS Employer  
Identification No.)

**1633 Broadway, Suite 22C,  
New York, New York 10019**  
(Address of principal executive offices)

**(212) 489-2100**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	DCTH	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

On September 6, 2023, Delcath Systems, Inc. (the "Company") released an updated corporate presentation on the "Events & Presentations" section of the Company's website at <https://delcath.com/investors/events-presentations/>. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

*The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference in any registration statement or other filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.*

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	<a href="#">Corporate Presentation.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DELCATH SYSTEMS, INC.

Date: September 6, 2023

By: /s/ Gerard Michel  
Name: Gerard Michel  
Title: Chief Executive Officer



Corporate Presentation  
(NASDAQ: DCTH)

September 6, 2023



## Forward-looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company’s ability to successfully commercialize the HEPZATO KIT; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of Delcath and third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for commercialized product; the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT; the timing and results of the Company’s clinical trials, our determination whether to continue a clinical trial program or to focus on other alternative indications, and the impact of the COVID-19 pandemic or other pandemics on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

The logo for Delcath, featuring the word "Delcath" in a white, sans-serif font. The letter "c" is stylized with a blue and green circular graphic element.

# Executive Summary

Delcath aims to be the leader in targeted, safe and highly-effective minimally-invasive treatments for patients with cancers of the liver.

## UNMET NEED LIVER CANCER

- Incidence US/EU
- >200K primary and metastatic liver tumors per year<sup>1-14</sup>
- Current local/regional treatments
- Cannot treat the whole liver
  - Targeted to visible and accessible tumors
  - Limited in their ability to retreat

## HEPATIC DELIVERY SYSTEM (HDS)

- HDS + Melphalan enables the Percutaneous Hepatic Perfusion (PHP) Procedure
- Delivers high dose chemotherapy to the entire liver
  - Limits systemic exposure
  - Minimally invasive, repeatable and well-tolerated
- US: HEPZATO KIT (Melphalan/HDS)  
EU: CHEMOSAT (HDS)

## COMPANY & CLINICAL PROGRAM

- FDA Approved 8/14/23
- Metastatic Ocular Melanoma (mUM)
  - Liver failure #1 cause of death in mUM
  - Response rates >36%
  - 1 Year OS\*\* = 80%
- Real World Evidence**
- >1k commercial treatments in EU
  - Multiple single center publications

Launch Expected Q4 '23

## LARGE MARKET OPPORTUNITY

- Near-term (mUM)\*
- Ultra orphan pricing dynamic
  - >\$600M TAM in US/EU
- Longer Term (CRC, ICC, Pancreatic, etc.)
- >>\$1B TAM
  - Investigator interest in more than 10 other indications

\* mUM – metastatic Uveal Melanoma, also known as metastatic Ocular Melanoma    \*\*Exploratory endpoint in FOCUS trial

# Limitations of Current Liver-Directed Therapies


## Trans Arterial Chemo Embolization (TACE)<sup>1</sup>

- » Beads obstruct blood flow to tumor and elute chemo
- » **50-60k treatments** per year in US (and growing)



## Y90<sup>2</sup>

- » Radioactive beads delivered into the tumor
- » **10-15k treatments per year** in US (and growing)



Majority of Treatment



Effective, but tumors recur & retreatment limited due to damaged vasculature



Diffuse disease: cannot be treated with a tumor-by-tumor modality



Many tumors are not imageable – micro-metastases are common

Delcath

# HEPZATO KIT™: Enables Percutaneous Hepatic Perfusion (PHP)

Repeatable, safe & effective liver-focused disease control


## ISOLATION

Hepatic venous flow is isolated, enabling 12x increased dose




## SATURATION

Melphalan (chemo) treats micro and macro lesions simultaneously



## FILTRATION

Proprietary filters remove greater than 85% of chemo from the body<sup>33</sup>



Delcath



# Liver-Dominant Cancers

High incidence with poor prognosis

Up to

80%

Many patients with liver metastases are not amenable to surgical resection largely due to extensive tumor burden<sup>17</sup>



## Liver: Common Site of Metastases




## Limited Effective Systemic Treatments

- » Systemic therapies - low efficacy
- » Immuno-oncology agents - become less effective in the presence of metastases



## Limited Overall Survival – Unresectable Liver Cancer

- » Often the life-limiting organ



Delcath

\*Metastatic Ocular Melanoma (mOM)<sup>14</sup>, Cholangiocarcinoma (ICC)<sup>15</sup>, Liver-dominant Breast Cancer (mBC)<sup>12</sup>, Metastatic Neuroendocrine Tumors (mNET)<sup>19</sup>, Metastatic Pancreatic Cancer (mPC)<sup>13</sup>, Metastatic Colorectal Cancer (mCRC)<sup>11,14</sup>, Hepatocellular carcinoma (HCC)<sup>17</sup>

# mUM: Beachhead Market Opportunity

High Unmet Need, Favorable Reimbursement Environment



## Unmet Need

- » >5,000 cases of primary ocular melanoma per year in the US/EU<sup>18</sup>  
~50% metastasize to the liver<sup>4,19</sup>
- » US TAM ~800 patients, Europe ~1,200 patients
- » Median survival up to 12 months.<sup>20</sup>
- » 55% of patients have no approved treatment option, most patients treated with multiple lines of therapy

## Low Risk Commercial Opportunity

- » FDA Approved 8/14/23
- » Commercial launch 4Q '23
- » Commercial team led by TheraSphere (BSX) veterans
- » Focused commercial effort: 20 US treatment centers @ 2 patients/week = ~70% TAM

## High Barrier to Entry

- » Orphan indication status allows for extended exclusivity
- » HEPZATO is a combination drug device regulated by CDER – no traditional ANDA pathway
- » IP around HEPZATO limits any 505(b)(2) follow-on

## Favorable US Commercial Economics


- » Favorable US reimbursement environment for ultra orphan outpatient MD administered drugs
- » KIMMTRAK® (tebentafusp-tebn) (approved 1Q '22 for ~45% of mUM population ) priced at an average of \$790K per patient, reported \$41.7M in 2Q '23

Delcath

# Patient Journey (Pre- Metastatic)



# Patient Journey (Post Metastatic)



# Liver metastases: a significant clinical problem in mUM



## Half of all patients with UM develop systemic metastases <sup>21,22</sup>

- The liver is involved in 90% of cases of metastatic disease <sup>21,22</sup>
- In 50% of mUM patients, the liver is the only site of metastasis <sup>21,22</sup>
- Most patients with mUM die from liver failure <sup>22</sup>
- 1-year OS rate of patients with metastatic disease in the liver is 13%; mOS with median survival ranging from 4 to 15 months <sup>24,25</sup>



mUM patients have micrometastases with or without the presence of radiologically visible metastases <sup>23</sup>



**Liver directed treatment, such as Isolated Hepatic Infusion\* (IHP), achieves better efficacy (ORR, PFS, PFS) compared to systemic therapy <sup>26</sup>**

IHP is an invasive surgical technique for delivering high doses of chemotherapy to the liver; procedure related mortality and morbidity prevented common usage. PHP is a minimally invasive, safer procedure which accomplishes the same goals as IHP and can be performed up to 6 times.

Delcath

## Diffuse/Miliary Metastatic Pattern in mUM

Diffuse disease is difficult to treat with current options

- ▶ Solitary liver lesions are often treated with surgery or ablation
- ▶ Radiographically metastatic Uveal Melanoma can initially present only as focal lesions
- ▶ As is often the case, the true nature of the disease may only be seen upon visual confirmation
- ▶ Traditional liver directed therapy mechanism of action is not ideal if a whole liver treatment is needed
- ▶ Whole organ therapy delivers medication to a specific organ or tissue through its blood supply, then filters out the medication to minimize systemic exposure



Actual patient sent for a liver resection based upon radiographic diagnosis\*

\* Data on File

Delcath

## Estimated 80%+ of mUM Patients Are Eligible

### 1 INDICATIONS AND USAGE

HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Indicated Patient Population includes ▶

*Treatment naïve and  
previously treated patients*

*No HLA genotype  
restrictions*

Delcath

# Box Warnings Managed By REMS

Risk Evaluation and Mitigation Strategy Program  
= *Training & Monitoring*

## WARNING: PERI-PROCEDURAL COMPLICATIONS, MYELOSUPPRESSION

- Severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events may occur via hepatic intra-arterial administration of HEPZATO. Assess patients for these adverse reactions during and for at least 72 hours following administration of HEPZATO [see *Warnings and Precautions (5.1)*].
- HEPZATO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the HEPZATO KIT REMS [see *Warnings and Precautions (5.2)*].
- Myelosuppression with resulting severe infection, bleeding, or symptomatic anemia may occur with HEPZATO. Monitor hematologic laboratory parameters and delay additional cycles of HEPZATO therapy until blood counts have improved. [see *Warnings and Precautions (5.3)*]

European experience has shown that the procedure can be safely conducted by Interventional Radiology team after appropriate training

REMS program goals are to standardize training, ensure consistent treatment methodology and monitor outcomes

Myelosuppression is a black box warning for generic melphalan, the management of which is standard practice for oncologists

Delcath





## FOCUS Trial

### Registration Clinical Trial for Patients with mUM

# FOCUS

- Multinational, multicenter, single-arm trial
- Efficacy Endpoints:
  - » Primary: Objective Response Rate (ORR) compared to meta-analysis of IO therapy
  - » Secondary: Duration of Response (DOR), Disease Control Rate (DCR), Overall Survival (OS), Progression Free Survival (PFS)
- 102 patients enrolled, 91 completed treatments at 23 centers in the US and EU
- HEPZATO Tx every 6-8 weeks up to a maximum of 6 cycles

## FOCUS Trial


### Single Arm Trial Efficacy Data in PI

Efficacy Endpoint	N (%)
ORR, n (%)	33 (36.3)
[95% CI]	[26.44, 47.01]
Median DOR, months	14
[95% CI]	[8.31-17.74]
DCR, n (%)	67 (73.6)
[95% CI]	[63.35, 82.31]

- 91 treated patients
- Trial powered to show an ORR advantage over a meta-analysis of Best Alternative Care (checkpoint inhibitors, chemotherapy, other liver directed therapy)
- Lower bound of FOCUS ORR (26.4) is significantly higher than the upper bound of the meta-analysis (8.3%)
- Prescribing Information includes ORR, DOR and response categories
- Full analysis with final data cut pending publication – manuscript in process

# HEPZATO Response Predicts Survival

## Kaplan Meier Curves in Treated Populations\*



CR	7	7	7	6	6	4	1	0			
PR	26	26	26	20	16	8	5	1	0		
SD	34	33	27	19	9	7	5	4	2	2	1
PD/ND	24	19	10	4	2	1	0				

## Exploratory Analyses\*

	CR (N=7)	PR (N=26)	SD (N=34)	PD/ND (N=24)
Status of OS, N (%)				
Events	1 (14.3)	17 (65.4)	29 (85.3)	20 (83.3)
Censored	6 (85.7)	9 (34.6)	5 (14.7)	4 (16.7)
Median OS (Months) †	NC	28.16	19.25	11.99
95% CI	[26.71, NC]	[23.46, 34.46]	[15.90, 23.00]	[8.18, 14.03]
<b>p-value‡</b>	<b>&lt;0.0001</b>			

CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease, ND=not done, BOR=best overall response  
 Note: NC = Not calculable, due to the number of events within the stratum (n=1)

† Kaplan-Meier estimates.

‡ Log-Rank test.

\* 02-Dec-2022 data cut, patients followed through May, 2023

Analysis Supports that ORR is Clinically Meaningful

# OS and PFS Trend Favorable Relative to Historical Results

Pre-Specified Exploratory Analyses\*

Secondary Endpoint	N (%)
Median OS, months	20.53
[95% CI]	[16.79, 25.26]
1 Year OS, K-M Probability Point Estimate	0.80
[95% CI]	[0.70, 0.87]
Median PFS, Months	9.03
[95% CI]	[6.34, 11.56]

\* 02-Dec-2022 data cut, patients followed through May, 2023

## Published mUM Prospective and Retrospective Studies\*

Clinical Study/Publication	Study Type	Treatment	N	Median OS (months)	1 year OS	Median PFS (months)
FOCUS	Single-Arm	Hepzato	91 <sup>AL</sup>	20.53	80%	9.03
Khoja et al 2019 <sup>33</sup>	Meta-Analysis	systemic and liver-directed therapies	912	10.2	NA	3.3
Rantala et al 2019 <sup>34</sup>	Meta-Analysis	systemic and liver-directed therapies	2,494	12.84	NA	NA
Piulats et al 2021 <sup>35</sup>	Single-Arm	ipi plus nivo	52 <sup>TN</sup>	12.7	NA	3.0
Heppt et al 2019 <sup>36</sup>	Single-Arm	ipi plus (pembro or nivo)	64 <sup>AL</sup>	16.1	NA	3.0
Nathan et al 2021 <sup>37</sup>	Randomized	tebentafusp	252 <sup>TN</sup>	21.7	73%	3.3
		control	126 <sup>TN</sup>	16	59%	2.9

TN = Treatment Naïve, AL = Any Line

\*Studies from 2019 or later with >50 patients

Ipi = ipilimumab, nivo = nivolumab, pembro = pembrolizumab

Delcath

## Adverse Events Primarily Hematological

	All Adverse Reactions N=95	
	All Grades (%)	Grades 3 or 4 (%)
Hypotension	13	3
Dyspnea	23	2
Abdominal Pain	39	1
Diarrhea	17	1
Musculoskeletal Pain	46	1
Hemorrhage	15	1
Nausea	57	0
Vomiting	35	0
Fatigue	65	0
Pyrexia	16	0
Groin Pain	11	0
Cough	15	0
Headache	19	0
Lethargy	12	0
Dizziness	11	0
Contusion	17	0
Decreased appetite	16	0

Most hematological side effects result from melphalan

Side effect profile similar to other cytotoxics commonly Used By Oncologists

Referring Centers

HEPZATO Treating Center



Trained Treating Team



## Patients Referred to Multidisciplinary Treatment Teams

Oncologists Are Generally the Decision Makers

# Training Key to Expanding Number of Treating Sites and Capacity

Multidisciplinary Teams to Be Expanded To Increase Both Training Capacity and Patient Flow



Delcath



# Plan To Launch at 10 Treating Sites


Leveraging EAP and Longitudinal Data to Build Referral Networks

## EAP – Currently 3 Sites

- Provide immediate access to patients
- First Commercial Sites
- Train new medical teams to use Hepzato after launch

## Leverage Longitudinal Data

- Partnered with data provider to access patient level longitudinal data with 3-week refresh
- Accurately map and quantify surveillance, referral and treatment patterns at the patient and MD level




Delcath

## Treating Centers – Current Targets for Launch

Institution	City	Status
Moffitt Cancer Center	Tampa, Florida	EAP - Open and Enrolling
Duke University	Durham, North Carolina	EAP - Open and Enrolling
University of Tennessee	Memphis, Tennessee	EAP - Open and Enrolling
Stanford University	Stanford, California	EAP - Plans to join
Ohio State University	Columbus, Ohio	EAP - Plans to join
Mayo Clinic Hospital	Jacksonville, Florida	EAP - Plans to join
HonorHealth	Scottsdale, Arizona	Confirmed interest in being a treating center
Thomas Jefferson University	Philadelphia, Pennsylvania	Confirmed interest in being a treating center
University of Miami	Miami, Florida	Confirmed interest in being a treating center

# Specialized, Targeted Sales Team

Two Complementary Teams of Representatives



## Hospital Representative

### Responsibilities

- Manage Treating Centers Including VAC/Formulary
- Support Treating Teams
- Facilitate REMS Compliance
- Generate Intra-Center Referrals
- Prospect and Open New Centers with Oncology Representative

## Oncology Representative

### Responsibilities

- Generate Inter-Center Referrals
- Support Hospital Rep / Generate Intra-Center Referrals
- Prospect and Open New Centers with Hospital Representative

# Reimbursement

HEPZATO will be billed as a drug with a J-Code



## Medicare Patients


- Initially a C-Code
- Majority of patients will be outpatient (2 midnight rule) with the drug directly covered by Medicare



## Private Payer Patients

- Private Payers for rare disease generally follow Medicare guidelines and we expect these patients to be treated as outpatients
- Prior-Authorization of patients might be needed, we are planning to contract out a hub service
- Centers of Excellence (Prospective Payment System (PPS) exempt and NCI designated Cancer Centers) have the leverage to negotiate favorable rates and reimbursement terms (our target sites are all either PPS exempt or NCI Cancer Centers)

# PHP Is ALREADY Part of Current NCCN Guidelines for mUM



## Regional Isolation Perfusion

Methods include isolated hepatic infusion (IHP), percutaneous hepatic perfusion (PHP), HAI, and embolization techniques. PHP is a simpler, less invasive alternative to IHP that can be repeated. It uses a double-balloon catheter inserted into the inferior vena cava to isolate hepatic venous blood that is then filtered extracorporeally.

# Components of Hospital Reimbursement

Assuming Outpatient Pass Through Status with C Code

**Drug**

- ASP+6% (CMS)
- Likely similar for commercial payers

**Healthcare Facility Fee**

- Highly variable based on coding – we do not “map” to any existing code
- Using existing codes is advised and should provide the hospital adequate payment

**“Physician” payment**

- Actually goes to hospital but still matters to MD
- Highly variable based on coding – we do not “map” to any existing code
- Using existing codes is advised and should provide the hospital adequate payment



**CPT Code mapping complete – while important, it will not have a meaningful impact on drug pricing decision**

# HEPZATO Pricing Consistent with Other Approved Therapy


At First Assessment (first time to discontinue treatment because of progression)			
Drug	Dose Cost*	Treatments #	Total cost
Kimmtrak	\$19,289	24	\$462,936
Hepzato	\$182,500	2	\$365,000

Mean Hepzato treatment vs. mean treatment duration of Kimmtrak (per pivotal trials)			
Drug	Dose Cost	Mean Treatments #	Total cost
Kimmtrak	\$19,289	41	\$790,849
Hepzato	\$182,500	4.1	\$748,250

Maximum Hepzato treatment vs. Annual treatment duration of Kimmtrak			
Drug	Dose Cost	Max / Annual Treatments #	Total cost
Kimmtrak	\$19,289	52	\$1,003,028
Hepzato	\$182,500	6	\$1,095,000

\*Dose Cost ASP calculated using 7/2023 CMS payment allowance limit

# Rapid Uptake for FDA Approved Treatment in mUM



## Demonstrated demand for FDA approved treatments for mUM

- KIMMTRAK - \$41.7 million in Q2 2023 US sales (\$167M annualized revenue)
- Only 45% of mUM patients are eligible for treatment with KIMMTRAK (unique MOA)
- KIMMTRAK captured an estimated 40% share of eligible patients within 12 months

## HEPZATO KIT approved August 14, 2023 to treat patients with liver dominant mUM

- mUM patients with liver involvement of <50% are eligible for treatment with HEPZATO
- HEPZATO would require <20% of eligible patients to achieve similar 4 quarter growth\*
- HEPZATO has no HLA genotype restrictions and will be the only FDA approved drug for 55% of all mUM patients, as well as for KIMMTRAK failure patients

## HEPZATO KIT is well positioned to capture a similar share of its TAM

- HEPZATO is more of a complement than a competitor to KIMMTRAK for patients eligible for KIMMTRAK
- HEPZATO EAP patients have included: 1st line stand alone treatment, 1st line treatment for those intending to receive KIMMTRAK, as 2nd line treatment, and as a 3rd line palliative treatment
- NCCN Guidelines currently state "regional isolation perfusion of the liver" as a recommended treatment
- "If disease is confined to the liver, regional therapies...should be considered. Since tebentafusp-tebn response rates are low, symptomatic patients may be better palliated by liver-directed treatment first...." NCCN Guidelines Melanoma Uveal V1.2023

\*Assuming a \$150,000 per kit cost and 4 kits per patient




# Clinical Rationale for Broad Development Effort

<p><b>PHP treats the entire liver and is not dependent on tumor location or number of lesions</b></p>	<p>➤ Promising ORR, DCR and PFS signals seen across multiple tumor types with CHEMOSAT in Europe and in earlier studies with IHP</p>
<p><b>Liver mets are often life limiting and reduce I/O efficacy</b></p>	<p>➤ HEPZATO is the only liver directed treatment which can repeatedly treat the whole liver</p> <p>➤ Early data supports that combination with I/O agents is safe and effective</p>
<p><b>Converting unresectable liver metastases into resectable</b></p>	<p>➤ Potential for significant improvement in survival</p>

# Strong Correlation of IHP and PHP Efficacy in mUM Patients

## IHP activity in CRC and NET

Meta-analysis of 8 mUM clinical studies <sup>27</sup>		
Endpoint	IHP (%)	PHP (%)
mOS	17.1	17.3
mPFS	7.2	9.6
hPFS	10	9.5
Complications	39.1	23.8
Mortality	5.5	1.8



IHP in mCRC	
Van Iersel <sup>28</sup>	ORR 50% mPFS 7.4 months mOS 24.8 months
Magge <sup>29</sup>	ORR 82% 1-year OS rate 91% 2-year OS rate 72%
Rothbart <sup>30</sup>	ORR 59% mTTP 7.7 months mOS 28.8 months
Bartlett <sup>31</sup>	ORR 76% DOR 8.5 months mOS 16 months
IHP in mNET	
Grover <sup>32</sup>	ORR 50% DOR 15 months mhPFS 7 months mOS 48 months

IHP, or Intrahepatic Perfusion, is an invasive surgical technique for delivering high doses of chemotherapy to the liver; procedure related mortality and morbidity prevented common usage. PHP is a minimally invasive, safer procedure which accomplishes the same goals as IHP and can be performed up to 6 times.

# Chemosat Has Been Used Across Multiple Tumor Types



- » CE Marked - available in ~23 centers in 4 countries
- » Delcath resumed direct sales on 3/1/22
- » ~1,400 commercial Chemosat kits shipped to the EU



- » Strong interest to fuel additional indications driven by HCP's
- » Results from over 20 retrospective and prospective trials published by independent investigators



- » NICE (UK) upgraded status from "Research" to "Special Status"
- » German reimbursement based on annual hospital special request ("ZE" process)
- » Broader usage pending FOCUS trial publication to support reimbursement

## CHEMOSAT Used In 13 Tumor Types

~70%: Metastatic Ocular Melanoma (mUM)

### Other Types Treated:

- Intrahepatic Cholangiocarcinoma (ICC)
- Hepatocellular Carcinoma (HCC)
- Metastatic Colorectal Cancer (mCRC)
- Metastatic Breast (mBreast)
- Pancreatic
- Metastatic Neuroendocrine Tumors (mNET)
- Metastatic Cutaneous Melanoma (mCM)

Delcath

# Rationale for Combining HEPZATO with IO Therapy

## Liver Metastases Suppress IO Therapy Efficacy

### nature medicine

Article | Published: 04 January 2021

**Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination**

### Science Immunology

SCIENCE IMMUNOLOGY • 30 Oct 2020 • Vol 9, Issue 52 • DOI: 10.1126/scimmunol.abd759

**Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis**

### HBSN HEPATOBIILIARY SURGERY AND NUTRITION

Hepatobiliary Surg Nutr. 2021 Aug; 10(4): 526-529.  
doi: 10.21037/hbsn-21-215

PMCID: PMC8351020  
PMID: 34430535

Liver metastases "siphon" off immunotherapy response

### frontiers in Oncology

Front Oncol. 2021; 11: 728018.  
Published online 2021 Aug 23. doi: 10.3389/fonc.2021.728018

PMCID: PMC8419351  
PMID: 34497771

**From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment**

### HEPATOLOGY AASLD


ORIGINAL ARTICLE

**Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice**


First published: 03 December 2021 | <https://doi.org/10.1002/hep.32266> | Citations: 2

Delcath

# CHOPIN: Phase mUM 1b/2 randomized study of PHP vs PHP+IO




% change of target lesions from baseline by response category



- N=7 in Phase 1b portion of the trial<sup>38</sup>
- RP2D: IPI 1mg/kg and NIVO 3mg/kg. Well tolerated, no DLTs or deaths.
- 1CR, 6 PR and 1 PD (85.7% ORR, 100% DCR) – meta-analysis of prior IO trials has shown ORR<<10%
- As of 11/15/22 the median follow-up was 29.1 months, the median PFS was 29.1 months, and the median duration of response was 27.1 months. All patients are still alive.
- 3 of 4 patients who subsequently experienced PD continued with treatment in the form of repeated Melphalan Chemosat treatments
- Ongoing randomized Phase 2 (control is Chemosat) has recruited 50% of N=76 patients and will provide an interim analysis at N=40 patients

# Market Expansion: Significant Investigator Interest



US TAM  
**>\$1B**  
 Per Year

Delcath

\*Metastatic Ocular Melanoma (mOM)<sup>14</sup>, Cholangiocarcinoma (ICC)<sup>15</sup>, Liver-dominant Breast Cancer (mBC)<sup>12</sup>, Metastatic Neuroendocrine Tumors (mNET)<sup>19</sup>, Metastatic Pancreatic Cancer (mPC)<sup>20</sup>, Metastatic Colorectal Cancer (mCRC)<sup>13,14</sup>, Hepatocellular carcinoma (HCC)<sup>17</sup>

# Multi-Disciplinary, Experienced Leadership Team

## GERARD MICHEL

Chief Executive Officer



- » 30+ yrs. pharma/medtech experience
- » C-suite roles at Vericel Corp, Biodel, & NPS
- » M.S. Microbiology, B.S. Biology & Geology from the Univ. of Rochester School of Medicine
- » M.B.A. Simon School of Business & Leadership

## JOHN PURPURA

Chief Operating Officer



- » Past VP and Exec Director roles of Reg. Affairs for Bracco Diagnostics
- » Held senior roles Sanofi-Aventis, Bolar Pharma, Luitpold Pharma & Eon Labs
- » M.S. Mgmt. & Policy and B.S. Chemistry and Biology at the State University of NY at Stony Brook

## BOARD OF DIRECTORS

John R. Sylvester	<i>Chairman</i>
Dr. Roger G. Stoll, Ph.D.	<i>Director</i>
Elizabeth Czerepak	<i>Director</i>
Steven Salamon	<i>Director</i>
Dr. Gil Aharon, Ph.D.	<i>Director</i>
Gerard Michel	<i>CEO</i>

## VOJISLAV VUKOVIC, MD PHD

Chief Medical Officer



- » Oncology dev. exec, global clinical expertise
- » Former CMO at Aileron, Taiho, Synta
- » MD, Univ. of Sarajevo | MSc, PhD, Univ. of Toronto
- » Published, AACR, ASCO, ASH, ESMO member

## KEVIN MUIR

General Manager, Interventional Oncology



- » 20+ yrs. of medtech/bioTx sales & marketing experience.
- » Held senior leadership roles at BTG, ClearFlow, Aragon Surgical, Kensey Nash Corporation, and Kyphon.
- » Field Artillery officer in the U.S. Army
- » B.S. in Management Systems Engineering at the U.S. Military Academy at West Point

## SANDRA PENNELL

SVP, Finance



- » 20+ years' biotech financial oversight experience
- » Manages global financial affairs, U.S. GAAP compliance
- » Led finance at Invivyd, VP at Vericel Corp
- » MSc, Accountancy, Univ. of Illinois

## Capital Structure and Share Information

Share Listing - Current	DCTH (NASDAQ)
Shares Outstanding <sup>a</sup>	20.3M
Cash and Cash Equivalents <sup>b</sup>	\$14.6M
Cash from 3Q Warrant Exercises <sup>c</sup>	\$35.0M
Warrants Outstanding <sup>d</sup>	15.56M
Stock Options Granted	2.9M
2023 Q2 Cash Burn <sup>e</sup>	\$9.6M
Debt <sup>f</sup>	\$9.8M
52 week Low – High <sup>g</sup>	\$2.34 - \$7.99
30d Average Daily Volume <sup>h</sup>	2,207,716

- a. As of June 30, 2023; includes 15.3M of Common plus 1.1M Preferred E & E-1, 2.9M of Preferred F-2 & 1.0M Pre-funded Warrants as converted
- b. As of June 30, 2023; (10-Q filing on August 9, 2023)
- c. 7.78M Tranche A warrants exercised 21 days after receipt of FDA approval for HEPZATO;
- d. As of June 30, 2023; 3.6M warrants at a \$10 exercise price, 7.78M Tranche A warrants for an aggregate exercise price \$35 million exercisable until the earlier of 3/31/2026 or 21 days receipt of FDA approval for HEPZATO (now all exercised); and 4.17M Tranche B warrants for an aggregate exercise price \$25 million exercisable until the earlier of 3/31/2026 or 21 days following recording at least \$10 million in quarterly U.S. revenue.
- e. Q2 Net cash used in operating activities (increase from Q1 2023 due to pay down of accrued liabilities)
- f. Includes \$5.0M of notes convertible at \$11.98 per common share equivalent,
- g. Used NASDAQ closing price information starting on September 4, 2022 – September 5, 2023
- h. 30-day average calculated between on August 5, 2023 – September 5, 2023

Delcath



# Delcath: Investment Summary



4Q launch in mUM



KIMMTRAK proving out significant commercial opportunity (~\$167M run rate) with 45% of the HEPZATO TAM



High penetration likely due to NCCN guidelines including PHP and equivalent OS as KIMMTRAK in more advance patient population



Management team experienced in commercializing high value, specialty products



Multiple 2023/2024 catalysts (Launch, CHOPIN data, Revenue Build)



Potential high value follow-on indications and strategic interest creates significant upside

THANK YOU

## References

1. Xu L, T, Funchain P, F, Bena J, F, Li M, Tarhini A, Berber E, Singh A, D: Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes. *Ocul Oncol Pathol* 2019;5:323-332. doi: 10.1159/000495113.
2. Lane AM, Kim IK, Gragoudas ES. Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma. *JAMA Ophthalmol*. 2018 Sep 1;136(9):981- 986.
3. Cancer.net Editorial Board (2020) Eye Cancer - Statistics. In: Cancer.Net. <https://www.cancer.net/cancer-types/eye-cancer/statistics>. Accessed 22 Jun 2020.
4. Ocular Melanoma Foundation. Treatment of Metastatic Disease. In: OMF – Metastatic Treatment. <http://www.ocularmelanoma.org/metstreatment.htm>. Accessed 22 Jun 2020.
5. Patel N, Benipal B. Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. *Cureus*. 2019;11(1):e3962. Published 2019 Jan 25.
6. United States Census Bureau. (2019) Monthly Population Estimates for the United States: April 1, 2010 to December 1, 2020 (NA-EST2019-01).
7. Cancer.net Editorial Board. (2020) Neuroendocrine Tumors - Statistics. In: Cancer.Net. <https://www.cancer.net/cancer-types/neuroendocrine-tumors/statistics>. Accessed 22 Jun 2020.
8. Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. *Ann Transl Med*. 2013;1(1):6. doi:10.3978/j.issn.2305-5839.2013.01.08.
9. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2018) ([www.seer.cancer.gov/popdata](http://www.seer.cancer.gov/popdata)), National Cancer Institute, DCCPS, Surveillance Research Program, released December 2019.
10. Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, Delvart V, Azoulay D, Bismuth H, Castaing D. Is liver resection justified for patients with hepatic metastases from breast cancer? *Ann Surg*. 2006 Dec;244(6):897-907; discussion 907-8. doi: 10.1097/01.sla.0000246847.02058.1b. PMID: 17122615; PMCID: PMC1856635.
11. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. *Breast Cancer Res Treat*. 1999 Jul;56(1):67-78. doi: 10.1023/a:1006285726561. PMID: 10517344.
12. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. *J Clin Oncol*. 1987 Jan;5(1):55-61. doi: 10.1200/JCO.1987.5.1.55. PMID: 3806159.
13. Cancer.net Editorial Board. (2020) Colorectal Cancer - Statistics. In: Cancer.Net. <https://www.cancer.net/cancer-types/colorectal-cancer/statistics>. Accessed 22 Jun 2020.
14. Ismaili N. Treatment of colorectal liver metastases. *World J Surg Oncol*. 2011;9:154. Published 2011 Nov 24. doi:10.1186/1477-7819-9-154.
15. Oweira H, Petrusch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, Schöb O, Giryas A, Decker M, Abdel-Rahman O. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. *World J Gastroenterol*. 2017 Mar 14;23(10):1872-1880. doi: 10.3748/wjg.v23.i10.1872. PMID: 28348494; PMCID: PMC5352929.

# References

16. [Key Statistics About Liver Cancer. American Cancer Society. Facts & Figures 2021. American Cancer Society. Atlanta, Ga. 2021.](#) Key Statistics About Liver Cancer. American Cancer Society. Facts and Figures 2021. American Cancer Society. Atlanta, GA 2021.
17. Reddy S, et al. Isolated hepatic perfusion for patients with liver metastases, *Ther Adv Med Oncol*. 2014 Jul; 6(4): 180-194.
18. Xu L, T, Funchain P, F, Bena J, F, Li M, Tarhini A, Berber E, Singh A, D: Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes. *Ocul Oncol Pathol* 2019;5:323-332. doi: 10.1159/000495113.
19. Lane AM, Kim IK, Gragoudas ES. Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma. *JAMA Ophthalmol*. 2018 Sep 1;136(9):981-986.
20. Karydis I, Gangi A, Wheeler MJ, et al. Percutaneous hepatic perfusion with Melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. *J Surg Oncol*. 2018;117(6):1170-1178. doi:10.1002/jso.24956
21. Krantz BA, et al. Uveal Melanoma: Epidemiology, Etiology, and Treatment of Primary Disease. *Clin Ophthalmol*. 2017;11:279-289
22. Eschelmann DJ et al. Transhepatic Therapies for Metastatic Uveal Melanoma. *Semin Intervent Radiol*. 2013;30(1):39-48.
23. Gill VT et al. Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem Tissue From Patients Without Coexisting Macrometastases. *Am J Clin Pathol*. 2023 Aug 1;160(2):164-174.
24. Lane AM, et al. Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma. *JAMA Ophthalmol*. 2018 Sep 1;136(9):981-986.
25. Carvajal RD, et al. Metastatic Disease from Uveal Melanoma: Treatment Options and Future Prospects. *Br J Ophthalmol*. 2017;101(1):38-44.
26. Olofsson BR, et al. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). *J Clin Oncol*. 2023 Jun 1;41(16):3042-3050.
27. Bethlehem MS et al. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. *Cancers (Basel)*. 2021 Sep 21;13(18):4726.
28. van Iersel LB et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients *Ann Oncol*. 2008;19:1127-34.
29. Magge D et al. A Phase I Trial of Isolated Hepatic Perfusion (IHP) Using 5-FU and Oxaliplatin in Patients with Unresectable Isolated Liver Metastases from Colorectal Cancer. *Ann Surg Oncol*. 2013 Jul;20(7):2180-7.
30. Rothbarth J et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. *Br J Surg*. 2003;90:1391-7.
31. Bartlett DL et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. *Surgery*. 2001 Feb;129(2):176-87
32. Grover A et al. Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases. *Surgery*. (2005). 136. 1176-82.
34. Khoja L, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. *Ann Oncol* 2019 Aug 1, 30(8): 1370-1380.

## References

34. Ranjala, E, et al. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. *Melanoma Res*. 2019 Dec; 29(6): 561–568
35. Piulats, J, et al. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). *Journal of Clinical Oncology* 39, no. 6 (February 20, 2021) 586-598.
36. Heppt, M, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. *J Immunotherap Cancer*. 2019 Nov 13;7(1):299.
37. Nathan, P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. *N Engl J Med* 2021; 385:1196-1206
38. Tong TML et al. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. *Cardiovasc Intervent Radiol*. 2023 Mar;46(3):350-359.
39. Rothbarth J, Pijl ME, Vahrmeijer AL, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. *Br J Surg*. 2003;90:1391–7.
40. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. *Br J Cancer*. 2000;82:1539–46.
41. Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Hulsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. *Ann Surg Oncol*. 2005;12:138–44.